Citations

Clear

9383 citation(s) found for "Thomas, PS".

Response to Mukhdomi and colleagues
Schwenk, Eric S. , Porter, Steven B , Schwenk, Eric S , Porter, Steven B.

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 4, 2023 | Volume: 49 | Issue: 9 | Pages: 696.2-697

10.1136/rapm-2023-104865 | PMID 37793913 Get It

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
Murthy, Hemant S. , Zhang, Mei‐Jie , Chen, Karen , Ahmed, Sairah , Ganguly, Siddhartha , Kansagra, Ankit , Michelis, Fotios V. , Nishihori, Taiga , Patnaik, Mrinal M. , Aljurf, Mahmoud , Arai, Yasuyuki , Badar, Talha , Ballen, Karen K. , Bejanyan, Nelli , Brown, Valerie I. , Martino, Rodrigo , Cahn, Jean‐Yves , Castillo, Paul , Černý, Jan , Copelan, Edward A. , Daly, Andrew , Freytes, César O. , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Jamy, Omer , Joseph, Jacinth , Kanakry, Christopher G. , Khera, Nandita , Krem, Maxwell M. , Kuwatsuka, Yachiyo , Lekakis, Lazaros J. , Liu, Hongtao , Modi, Dipenkumar , Munshi, Pashna N. , Palmisiano, Neil , Rizzieri, David A. , Seo, Sachiko , Sharma, Akshay , Sohl, Melhm, Solomon, Scott R. , Ulrickson, Matthew L. , Üstün, Celalettin , Poel, Marjolein van der , Verdonck, Leo F. , Wagner, John L. , Wang, Trent , Wirk, Baldeep , Zeidan, Amer M. , Litzow, Mark R. , Weisdorf, Daniel J. , Saber, Wael , Kharfan‐Dabaja, Mohamed A. , Kansagra, Ankit , Michelis, Fotios V , Nishihori, Taiga , Patnaik, Mrinal , Arai, Yasuyuki , Badar, Talha , Bejanyan, Nelli , Bhatt, Vijaya Raj , Chhabra, Saurabh , Dholaria, Bhagirathbhai R , Diaz Perez, Miguel Angel , Freytes, Cesar O , Hashmi, Shahrukh K , Jamy, Omer , Krem, Maxwell M , Lazarus, Hillard M , Liu, Hongtao , Modi, Dipenkumar , Mussetti, Alberto , Patel, Sagar , Shah, Mithun V , Sharma, Akshay , Ustun, Celalettin , Wagner, John , Litzow, Mark R. , Hourigan, Christopher S , Weisdorf, Dan , Kharfan-Dabaja, Mohamed A , Murthy, Hemant S , Martino, Rodrigo , Ahmed, Sairah , Zeidan, Amer M , Deotare, Uday , Abid, Muhammad Bilal , Bacher, Ulrike , Badawy, Sherif M. , Battiwalla, Minoo , Beitinjaneh, Amer , Bhatt, Vijaya Raj , Chhabra, Saurabh , Dholaria, Bhagirathbhai , Díaz, Miguel Ángel , Grunwald, Michael R. , Lazarus, Hillard M. , Mussetti, Alberto , Patel, Sagar S. , Shah, Meera , Kebriaei, Partow , Hourigan, Christopher S.

Mayo Clinic

Blood Advances | October 4, 2023 | Volume: 7 | Issue: 22 | Pages: 7007-7016

10.1182/bloodadvances.2023011308 | PMID 37792849 Get It

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT) offers durable remissions in patients with BPDCN. We report an analysis of patients with BPDCN who received an allo-HCT, using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We identified 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007 and 2018. The 5-year overall survival (OS), disease-free survival (DFS), relapse, and nonrelapse mortality (NRM) rates were 51.2% (95% confidence interval [CI], 42.5-59.8), 44.4% (95% CI, 36.2-52.8), 32.2% (95% CI, 24.7-40.3), and 23.3% (95% CI, 16.9-30.4), respectively. Disease relapse was the most common cause of death. On multivariate analyses, age of ≥60 years was predictive for inferior OS (hazard ratio [HR], 2.16; 95% CI, 1.35-3.46; P = .001), and higher NRM (HR, 2.19; 95% CI, 1.13-4.22; P = .02). Remission status at time of allo-HCT (CR2/primary induction failure/relapse vs CR1) was predictive of inferior OS (HR, 1.87; 95% CI, 1.14-3.06; P = .01) and DFS (HR, 1.75; 95% CI, 1.11-2.76; P = .02). Use of myeloablative conditioning with total body irradiation (MAC-TBI) was predictive of improved DFS and reduced relapse risk. Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, whereas MAC-TBI predicted for less relapse and improved DFS. Novel strategies incorporating allo-HCT are needed to further improve outcomes.
Genomic analysis of spermatocytic tumors demonstrates recurrent molecular alterations in cases with malignant clinical behavior
Gupta, Sounak , Sholl, Lynette M. , Osunkoya, Adeboye O. , Gordetsky, Jennifer , Cornejo, Kristine M. , Dvindenko, Eugénia, Hirsch, Michelle S. , Rowsey, Ross, Jiménez, Rafael E. , Cheville, John C. , Colecchia, Maurizio , Ricci, Costantino , Ulbright, Thomas M. , Snuderl, Matija , Rowsey, Ross A, Acosta, Andrés M , Gordetsky, Jennifer B , Yang, Yiying , Michalova, Kvetoslava , Maclean, Fiona M. , Snuderl, Matija , Anderson, William J. , Sadow, Peter M. , Berney, Daniel M. , Acosta, Andrés

Mayo Clinic

The Journal of Pathology | October 4, 2023 | Volume: 262 | Issue: 1 | Pages: 50-60

10.1002/path.6210 | PMID 37792634 Get It

Abstract Spermatocytic tumor (ST) is a rare type of germ cell tumor that occurs exclusively in the postpubertal testis and typically affects elderly men. Most STs are benign, but rare cases exhibit aggressive clinical behavior, often in association with transition to sarcomatoid histology. Limited molecular analyses have been performed on STs; therefore, their genomic and epigenomic features remain incompletely described. Twenty‐seven samples from 25 individual patients were analyzed with a combination of DNA sequencing panels, genomic methylation profiling, SNP array, isochromosome (12p) [i(12p)] FISH, and immunohistochemistry. The series included five metastasizing tumors (three with sarcomatoid transformation, one anaplastic, and one conventional) and 20 non‐metastasizing tumors (14 anaplastic and six conventional). Anaplastic tumors comprised a monomorphic population of intermediate‐sized neoplastic cells, as previously described. Multiomic analyses demonstrated that there were two genomic subgroups of STs: one with diploid genomes and hotspot RAS / RAF variants and the other with global ploidy shift and absence of recurrent mutations. Relative gain of chromosome 9 was a consistent finding in both subgroups. A comparison of metastasizing and non‐metastasizing cases demonstrated that aggressive behavior was associated with the acquisition of pathogenic TP53 mutations and/or relative gains of 12p/i(12p). In cases with sarcomatoid transformation, TP53 mutations seem to underlie the transition to sarcomatoid histology. Genomic methylation analysis demonstrated that aggressive cases with gains of 12p cluster closer to pure seminomas than to STs without gains of 12p. In conclusion, STs include two genomic subgroups, characterized by global ploidy shifts without recurrent mutations and diploid genomes with RAS / RAF hotspot mutations, respectively. Biologic progression was associated with relative gains of 12p and TP53 mutations. The findings in STs with relative gains of 12p suggest that they may exhibit biologic characteristics akin to those seen in germ cell neoplasia in situ ‐related germ cell tumors rather than non‐germ cell neoplasia in situ ‐derived STs. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Detection of Early Myocardial Dysfunction by Imaging Biomarkers in Cancer Patients Undergoing Photon Beam vs. Proton Beam Radiotherapy: A Prospective Study
Abbasi, Muhannad , Bruno, Giulia , Stefano, Cristina Di , Bello, Laura Garcia, Corbin, Kimberly S. , Whitaker, Thomas J. , Pellikka, Patricia A. , Mutter, Robert W. , Villarraga, Hector R. , Abbasi, Muhannad Aboud , Di Stefano, Cristina , Garcia Bello, Laura, Pellikka, Patricia A , Laack, Nadia N.

Mayo Clinic

Journal of Cardiovascular Development and Disease | October 4, 2023 | Volume: 10 | Issue: 10 | Pages: 418

10.3390/jcdd10100418 | PMID 37887865 Get It

1. Background: We sought to determine acute and subacute changes in cardiac function after proton beam (PBT) and photon beam (PhT) radiotherapy (RT) using conventional and two-dimensional speckle tracking echocardiography (2D-STE) in patients with malignant breast and thoracic tumors. 2. Methods: Between March 2016 and March 2017, 70 patients with breast or thoracic cancer were prospectively enrolled and underwent transthoracic echocardiography with comprehensive strain analysis at pretreatment, mid-treatment, end of treatment, and 3 months after RT. 3. Results: PBT was used to treat 44 patients; PhT 26 patients. Mean ± SD age was 55 ± 12 years; most patients (93%) were women. The median (interquartile range) of the mean heart dose was lower in the PBT than the PhT group (47 [27–79] vs. 217 [120–596] cGy, respectively; p < 0.001). Ejection fraction did not change in either group. Only the PhT group had reduced systolic tissue Doppler velocities at 3 months. 2D-STE showed changes in endocardial and epicardial longitudinal, radial, and circumferential early diastolic strain rate (SRe) in patients undergoing PhT (global longitudinal SRe, pretreatment vs. end of treatment (p = 0.04); global circumferential SRe, pretreatment vs. at 3-month follow-up (p = 0.003); global radial SRe, pretreatment vs. at 3-month follow-up (p = 0.02) for endocardial values). Epicardial strain values decreased significantly only in patients treated with PhT. Patients in the PhT group had a significant decrease in epicardial global longitudinal systolic strain rate (GLSRs) (epicardial GLSRs, at baseline vs. at end of treatment [p = 0.009]) and in GCSRe and GRSRe (epicardial GCSRe, at baseline vs. at 3-month follow-up (p = 0.02); epicardial GRSRe, at baseline vs. at 3-month follow-up (p = 0.03)) during treatment and follow-up. No changes on 2D-STE were detected in the PBT group. 4. Conclusions: Patients who underwent PhT but not PBT had reduced tissue Doppler velocities and SRe values during follow-up, suggesting early myocardial relaxation abnormalities. PBT shows promise as a cardiac-sparing RT technology.
Lithium Response in Bipolar Disorder is Associated with Focal Adhesion and PI3K-Akt Networks: A Multi-omics Replication Study
Ou, Anna , Adli, Mazda , Akiyama, Kazufumi , Akula, Nirmala , Amare, Azmeraw T. , Ardau, Raffaella , Arias, Bárbara , Aubry, Jean‐Michel , Bauer, Michael , Benabarre, Antonio , Bengesser, Susanne , Abesh, Bhattacharjee, Bui, Elise T. , Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Clark, Scott R. , Cousins, David A. , Cruceanu, Cristiana , Degenhardt, Franziska , Ferensztajn‐Rochowiak, Ewa , Forstner, Andreas J. , Frisén, Louise , Frye, Mark A. , Gard, Sébastien, Grof, Paul , Gruber, Oliver , Kahn, Jean‐Pierre, Kassem, Layla, Kittel‐Schneider, Sarah , Dalkner, Nina , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leckband, Susan G. , López‐Jaramillo, Carlos , Maj, Mario , Mattheisen, Manuel , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , Nöthen, Markus M. , Ösby, Urban, Perlis, Roy H. , Pfennig, Andrea , Potash, James B. , Schalling, Martin , Schubert, Klaus Oliver , Schweizer, Barbara , Severino, Giovanni , Shekhtman, Tatyana , Shilling, Paul D. , Shimoda, Kazutaka , Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Tighe, Sarah K., Volkert, Julia, Witt, Stephanie H. , Zandi, Peter P. , Zompo, Maria Del , Ou, Anna , Alda, Martin , Amare, Azmeraw , Arias, Bárbara , Bauer, M , Baune, Bernhard , Biernacka, Joanna , Chen, Hsi-Chung , Clark, Scott , Cruceanu, Cristiana , Czerski, Piotr , DePaulo, J Raymond , Etain, B , Forstner, Andreas J , Frye, Mark , Fullerton, Janice M , Garnham, Julie , Grigoroiu-Serbanescu, Maria , Hashimoto, Ryota , Hauser, Joanna , Heilbronner, Urs , Hou, Liping , Jamain, Stéphane , Kato, Tadafumi , Kuo, Po-Hsiu , Kusumi, Ichiro , Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Marie-Claire, Cynthia , McMahon, Francis , Mitchell, Philip B , Mitjans, Marina , Nievergelt, Caroline M , Nöthen, Markus M , Novak, Tomas , Ozaki, Norio , Papiol, Sergi , Reif, Andreas , Reininghaus, Eva , Rietschel, Marcella , Rouleau, Guy Armand , Rybakowski, Janusz K , Schalling, Martin , Schofield, Peter R , Schubert, Klaus Oliver , Schulze, Thomas , Severino, Giovanni , Shilling, Paul , Shimoda, Kazutaka , Squassina, Alessio , Turecki, Gustavo , Vieta, E , Witt, Stephanie H , Wray, Naomi , Del Zompo, Maria , Cichon, Sven , López-Jaramillo, Carlos , Kittel-Schneider, Sarah , McCarthy, Michael , Perlis, Roy H , Kelsoe, John R , Jiang, Qingfei , Alda, Martin , Backlund, Lena , Banzato, Cláudio E. M. , Bellivier, Frank , Biernacka, Joanna M. , Chen, Guo‐Bo , Chen, Hsi‐Chung , Colom, Francesc , Czerski, Piotr M. , Dantas, Clarissa de Rosalmeida , Dayer, Alexandre G. , Étain, Bruno , Falkai, Peter , Fellendorf, Frederike T. , Fullerton, Janice M. , Goes, Fernando , Grigoroiu‐Serbânescu, Maria , Hashimoto, Ryota , Heilbronner, Urs , Herms, Stefan , Hoffmann, Per , Hofmann, Andrea , Jamain, Stéphane , Jiménez, Esther , Kato, Tadafumi , König, Barbara , Kuo, Po‐Hsiu , Dalkner, Nina , Leboyer, Marion , MacQUEEN, GLENDA M. , Manchia, Mirko , Martinsson, Lina , McElroy, Susan L. , McMahon, Francis J. , Monteleone, Palmiero , Novák, Tomáš , Ozaki, Norio , Papiol, Sergi , Reich‐Erkelenz, Daniela , Reif, Andreas , Schofield, Peter R. , Seemüller, Florian , Squassina, Alessio , Stopková, Pavla , Tortorella, Alfonso , Turecki, Gustavo , Vieta, Eduard , Wright, Adam, Young, Trevor

Mayo Clinic

No container title available | October 3, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3258813/v1 | PMID 37886563 Get It

Abstract Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study of the Pharmacogenomics of Bipolar Disorder (PGBD) sample combining transcriptomic and genomic data, we found that focal adhesion, the extracellular matrix (ECM), and PI3K-Akt signaling networks were associated with response to lithium. In this study, we replicated the results of our previous study using network propagation methods in a genome-wide association study of an independent sample of 2,039 patients from the International Consortium on Lithium Genetics (ConLiGen) study. We identified functional enrichment in focal adhesion and PI3K-Akt pathways, but we did not find an association with the ECM pathway. Our results suggest that deficits in the neuronal growth cone and PI3K-Akt signaling, but not in ECM proteins, may influence response to lithium in BD.
Corrigendum to “Obesity Does Not Increase Complication Rate of Percutaneous Epicardial Access”
Wan, Siu‐Hin , KILLU, AMMARM, Hodge, David O. , Packer, Douglas L. , Mulpuru, Siva K. , Asirvatham, Samuel J. , Munger, Thomas M. , Friedman, Paul A. , Asirvatham, Samuel J , Killu, Ammar M.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | October 1, 2023 | Volume: 25 | Issue: 12 | Pages: 1419-1419

10.1111/jce.12581 Get It

Microvascular Free Flap Outcomes in Maxillectomy Defects from Invasive Fungal Sinusitis
Rao, Shilpa M., Knott, P. Daniel , Sweeny, Larissa , Domack, Aaron , Tang, Alice , Patel, Rusha , Pittman, Amy , Gardner, James Reed , Moreno, Mauricio A. , Sunde, Jumin , Cave, Taylor B., Knight, Nicolaus D., Greene, Ben, Pipkorn, Patrik , Joshi, Arjun S. , Ji, Keven Seung Yong , Yang, Sara , Wax, Mark K. , Thomas, Carissa M. , Gardner, J Reed , Chang, Brent A , Wax, Mark K , Thomas, Carissa M , Sweeny, Larissa , Rao, Shilpa M., Thakkar, Punam , Chang, Brent A.

Mayo Clinic

The Laryngoscope | September 29, 2023 | Volume: 134 | Issue: 4 | Pages: 1642-1647

10.1002/lary.31081 | PMID 37772913 Get It

ObjectivesMicrovascular free tissue transfer is routinely used for reconstructing midface defects in patients with malignancy, however, studies regarding reconstructive outcomes in invasive fungal sinusitis (IFS) are lacking. We aim to describe outcomes of free flap reconstruction for IFS defects, determine the optimal time to perform reconstruction, and if anti‐fungal medications or other risk factors of an immunocompromised patient population affect reconstructive outcomes.MethodsRetrospective review of reconstruction for IFS (2010–2022). Age, BMI, hemoglobin A1c, number of surgical debridements, and interval from the last debridement to reconstruction were compared between patients with delayed wound healing versus those without. Predictor variables for delayed wound healing and the effect of time on free flap reconstruction were analyzed.ResultsTwenty‐seven patients underwent free flap reconstruction for IFS. Three patients were immunocompromised from leukemia and 21 had diabetes mellitus (DM). Patients underwent an average of four surgical debridements for treatment of IFS. The interval from the last IFS debridement to flap reconstruction was 5.58 months (±5.5). Seven flaps (25.9%) had delayed wound healing. A shorter interval of less than 2 months between the last debridement for IFS and reconstructive free flap procedure was associated with delayed wound healing (Fisher Exact Test p = 0.0062). Other factors including DM, BMI, HgA1c, and bone reconstruction were not associated with delayed wound healing.ConclusionPatients with maxillectomy defects from IFS can undergo microvascular‐free flap reconstruction with good outcomes while on anti‐fungal medication. Early reconstruction in the first 2 months after the last IFS debridement is associated with delayed wound healing.Level of Evidence4 Laryngoscope, 134:1642–1647, 2024
Imaging Characteristics of and Multidisciplinary Management Considerations for Atypical Ductal Hyperplasia and Flat Epithelial Atypia: Review of Current Literature
Harper, Laura K , Carnahan, Molly B. , Bhatt, Asha A. , Simmons, Curtis , Patel, Bhavika , Downs, Erinn , Pockaj, Barbara A. , Yancey, Kristina , Eversman, Sarah , Sharpe, Richard E. , Simmons, Curtis L , Patel, Bhavika K , Eversman, Sarah E, Harrison, Molly

Mayo Clinic

RadioGraphics | September 28, 2023 | Volume: 43 | Issue: 10 | Pages: No page available

10.1148/rg.230016 | PMID 37768862 Get It

Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes
Ghali, Amer El , Alosaimy, Sara , Lucas, Kristen , Tupayachi-Ortiz, Maria G., Vemula, Raaga, Wadle, Carly , Hamad, Yasir , Zeuli, John D. , Fiske, Christina T. , Simonyan, Anahit, Cimino, Christo , Mammadova, Mehriban, Umana, Virginia, Butt, Saira , Molina, Kyle C. , Thomas, Michael A. , Kaip, Emily A, Gore, Tristan, Howard, Catessa, Cabanilla, M. Gabriela , Frens, Jeremy J , Barger, Melissa, Ong, Aaron, Rybak, Michael J. , El Ghali, Amer , Webb, Andrew J, Rybak, Michael J , Morrisette, Taylor , Philley, Julie V. , Mejía-Chew, Carlos , Stevens, Ryan W. , Webb, Andrew , Hasbun, Rodrigo , Bouchard, Jeannette L. , Holger, Dana J. , Cohen, Keira A.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | September 28, 2023 | Volume: 67 | Issue: 10 | Pages: No page available

10.1128/aac.00824-23 | PMID 37768312 Get It

ABSTRACT Infections due to nontuberculous mycobacteria (NTM) continue to increase in prevalence, leading to problematic clinical outcomes. Omadacycline (OMC) is an aminomethylcycline antibiotic with FDA orphan drug and fast-track designations for pulmonary NTM infections, including Mycobacteroides abscessus (MAB). This multicenter retrospective study across 16 U.S. medical institutions from January 2020 to March 2023 examined the long-term clinical success, safety, and tolerability of OMC for NTM infections. The cohort included patients aged ≥18 yr, who were clinically evaluable, and` had been treated with OMC for ≥3 mo without a previous diagnosis of cystic fibrosis. The primary outcome was 3 mo clinical success, with secondary outcomes including clinical improvement and mortality at 6- and 12 mo, persistence or reemergence of infection, adverse effects, and reasons for OMC utilization. Seventy-five patients were included in this analysis. Most patients were female (48/75, 64.0%) or Caucasian (58/75, 77.3%), with a median (IQR) age of 59 yr (49–67). Most had NTM pulmonary disease (33/75, 44.0%), skin and soft tissue disease (19/75, 25.3%), or osteomyelitis (10/75, 13.3%), and Mycobacterium abscessus (60/75, 80%) was the most commonly isolated NTM pathogen. The median (IQR) treatment duration was 6 mo ( 4 – 14 ), and the most commonly co-administered antibiotic was azithromycin (33/70, 47.1%). Three-month clinical success was observed in 80.0% (60/75) of patients, and AEs attributable to OMC occurred in 32.0% (24/75) of patients, leading to drug discontinuation in 9.3% (7/75).
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Coelho, Teresa , Dasgupta, Noel R., Parman, Yeşim , França, Marcondes C. , Guo, Yuh‐Cherng , Wixner, Jonas , Ro, Long‐Sun , Calandra, Cristian , Kowacs, Pedro André , Weiler, Markus , Jung, Shiangtung W., Büchele, Gustavo, Chen, Jersey , Hughes, Steven G. , Schneider, Eugene, Viney, Nicholas J. , Masri, Ahmad , Gertz, Morie R., Ando, Yukio, Khella, Sami, Dyck, P. James B. , Investigators, NEURO-TTRansform, Gane, Edward , Dávila, Lucía Galán, Mezei, Michelle M. , Moreno, Juan González, Cintas, Pascal , Traub, Rebecca , Khoury, Julie, Estol, Conrado J. , Polydefkis, Michael , Brannagan, Thomas H., Rugiero, Marcelo, Distad, B. Jane, Papanicolaou, Eleni Zamba, Lin, Kon‐Ping, Benson, Merrill D., Scheinberg, Morton , Gillmore, Julian D , Marques, Wilson , Chao, Chi‐Chao , Berk, John L. , Obici, Laura , Barroso, Fábio , Conceição, Isabel , Brambatti, Michela , Gertz, Morie A. , Ando, Yukio, Gillmore, Julian D. , Waddington‐Cruz, Márcia , Investigators, NEURO-TTRansform, Mazzeo, Anna Teresa , Papagianni, Aikaterini E. , Dimachkie, Mazen M. , Zaganas, Ioannis V. , Luigetti, Marco , Pareyson, Davide , Needham, Merrilee , Adams, David , Bril, Vera , Attarian, Shahram , Lin, Kon‐Ping

Mayo Clinic

JAMA | September 28, 2023 | Volume: 330 | Issue: 15 | Pages: 1448

10.1001/jama.2023.18688 | PMID 37768671 Get It

Importance Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy. Design, Setting, and Participants NEURO-TTRansform was an open-label, single-group, phase 3 trial conducted at 40 sites across 15 countries (December 2019-April 2023) in 168 adults with Coutinho stage 1 or 2 ATTRv polyneuropathy, Neuropathy Impairment Score 10-130, and a documented TTR variant. Patients treated with placebo from NEURO-TTR ( NCT01737398 ; March 2013–November 2017), an inotersen trial with similar eligibility criteria and end points, served as a historical placebo (“placebo”) group. Interventions Subcutaneous eplontersen (45 mg every 4 weeks; n = 144); a small reference group received subcutaneous inotersen (300 mg weekly; n = 24); subcutaneous placebo weekly (in NEURO-TTR; n = 60). Main Outcomes and Measures Primary efficacy end points at week 65/66 were changes from baseline in serum transthyretin concentration, modified Neuropathy Impairment Score +7 (mNIS+7) composite score (scoring range, –22.3 to 346.3; higher scores indicate poorer function), and Norfolk Quality of Life Questionnaire–Diabetic Neuropathy (Norfolk QoL-DN) total score (scoring range, –4 to 136; higher scores indicate poorer quality of life). Analyses of efficacy end points were based on a mixed-effects model with repeated measures adjusted by propensity score weights. Results Among 144 eplontersen-treated patients (mean age, 53.0 years; 69% male), 136 (94.4%) completed week-66 follow-up; among 60 placebo patients (mean age, 59.5 years; 68% male), 52 (86.7%) completed week-66 follow-up. At week 65, adjusted mean percentage reduction in serum transthyretin was −81.7% with eplontersen and −11.2% with placebo (difference, −70.4% [95% CI, −75.2% to −65.7%]; P &amp;lt; .001). Adjusted mean change from baseline to week 66 was lower (better) with eplontersen vs placebo for mNIS+7 composite score (0.3 vs 25.1; difference, −24.8 [95% CI, −31.0 to −18.6; P &amp;lt; .001) and for Norfolk QoL-DN (−5.5 vs 14.2; difference, −19.7 [95% CI, −25.6 to −13.8]; P &amp;lt; .001). Adverse events by week 66 that led to study drug discontinuation occurred in 6 patients (4%) in the eplontersen group vs 2 (3%) in the placebo group. Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group. Conclusions and Relevance In patients with ATTRv polyneuropathy, the eplontersen treatment group demonstrated changes consistent with significantly lowered serum transthyretin concentration, less neuropathy impairment, and better quality of life compared with a historical placebo. Trial Registration ClinicalTrials.gov Identifier: NCT04136184 ; EU Clinical Trials Register: EudraCT 2019-001698-10